Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

I-Mab Completes $104 Million NASDAQ IPO to Develop Biologics Portfolio

I-Mab Announces Terms for $100 Million US IPO; Starts China Trial of Immunoncology Drug

Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session

Alphamab Oncology Tees Up $350 Million Hong Kong IPO

Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China